MedTrace Logo

A Protocol of the Canadian Prospective Study for Hepatocellular Carcinoma Surveillance Using Biomarkers

NCT02272504 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2500

Last updated 2024-07-23

No results posted yet for this study

Summary

The objective of this study is to evaluate the clinical effectiveness of biomarkers, alpha-fetoprotein (AFP), Lens culinaris agglutinin-reactive fraction of AFP (AFP-L3), and des-gamma-carboxy prothrombin (DCP), for surveillance program patients whose hepatocellular carcinoma (HCC) development may be potentially missed by ultrasound (US). This study expects to demonstrate that addition of biomarkers will increase the detection rate by at least 10%.

Conditions

  • Cirrhosis
  • Chronic Liver Diseases

Sponsors & Collaborators

  • Wako Life Sciences

    lead INDUSTRY

Principal Investigators

  • Feld Jordan, MD · Toronto General Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-08-31
Primary Completion
2020-12-31
Completion
2021-02-28

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02272504 on ClinicalTrials.gov